Keros Therapeutics (KROS) EBITDA Margin (2019 - 2025)
Keros Therapeutics (KROS) reported EBITDA Margin of 5072.79% for Q4 2025, down 1555586.0% on a YoY basis from N/an in Q4 2024, and down 4602.82% quarter-over-quarter from 107.87% in Q3 2025.
Keros Therapeutics (KROS) EBITDA Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported EBITDA Margin for 6 years, with the latest figure at 5072.79% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 1555586.0% year-over-year to 5072.79%; the trailing twelve-month figure through Dec 2025 stood at 27.66% (down 17566650.0% YoY), and the FY2025 full-year result was 27.69%, changed N/A from the prior year.
- EBITDA Margin for Q4 2025 stood at 5072.79%, down from 107.87% in the prior quarter.
- The five-year high for EBITDA Margin was 10483.07% in Q4 2024, with the low at 541000.0% in Q3 2023.
- Historically, EBITDA Margin has averaged 54468.25% across 5 years, with a median of 219.16% in 2025.
- Annual changes were most pronounced in 2024 — EBITDA Margin jumped 52588222 bps — and 2025, when it plunged 1555586 bps.
- Keros Therapeutics' EBITDA Margin stood at 27.18% in 2021, then plunged by 393 bps to 134.03% in 2022, then plunged by 24137 bps to 32486.01% in 2023, then jumped by 132 bps to 10483.07% in 2024, then plunged by 148 bps to 5072.79% in 2025.
- The last three EBITDA Margin figures came in at 5072.79% (Q4 2025), 107.87% (Q3 2025), and 219.16% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -5,072.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,072.79% |
| Sep 30, 2025 | -107.87% |
| Jun 30, 2025 | -219.16% |
| Mar 31, 2025 | 71.97% |
| Dec 31, 2024 | 10,483.07% |
| Sep 30, 2024 | -15,117.78% |
| Dec 31, 2023 | -32,486.01% |
| Sep 30, 2023 | -541,000.00% |
| Mar 31, 2022 | -134.03% |
| Dec 31, 2021 | -27.18% |
| Jun 30, 2021 | -15,541.00% |
| Dec 31, 2019 | -109.12% |
| Sep 30, 2019 | -93.04% |
| Jun 30, 2019 | -106.04% |
| Mar 31, 2019 | -114.32% |